OVERVIEW

Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC is organized by i3 Health.

Dates Available:
August 1, 2023 - July 31, 2024

Statement Of Need:
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the United States, non–small cell lung cancer (NSCLC) accounts for 81% of all lung cancer diagnoses (Cancer.net, 2023). Therapeutic options, survival rates, and outcomes for NSCLC are dramatically impacted by the disease stage. For patients with early-stage disease, radical surgery is the mainstay of treatment; however, patients have a significant risk of relapse following surgery and local treatment. Numerous novel therapeutic approaches, including the use of molecular biomarkers and the development of targeted agents and immune checkpoint inhibitors, are under investigation for early-stage NSCLC, contributing to a growing arsenal of treatment options for this disease (Indini et al., 2020). In this activity, Helena A. Yu, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide expert perspectives on diagnosis, identification of biomarkers, and efficacy and safety data of novel adjuvant therapies to improve survival outcomes for patients with early-stage NSCLC.

Learning Objectives:
Upon completion of this activity, participants should be able to

Identify the correct tumor stage and appropriate management approach for NSCLC based on the latest evidence
Distinguish biomarkers for early-stage NSCLC that can inform individualized treatment strategies
Appraise efficacy and safety data of novel adjuvant therapies for patients with NSCLC as elucidated by recent clinical trials
Apply strategies to prevent and mitigate adverse events associated with novel adjuvant therapies for early-stage NSCLC

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non–small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!

ACCREDITATION & CREDITS

Jointly Accredited Provider:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants:
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development:
A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.9 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.

1 Contact Hour

1 AMA PRA Category 1 Credit™

1 MOC

1 Hours

FACULTY

Helena A. Yu

MDOncology, Internal Medicine

TARGET AUDIENCE

PhysicianNursingPhysician AssistantOncologistsFamily PhysiciansHealthcare ProfessionalsGeneral PhysicianNursesHematologistSurgical OncologistsFamily practice physiciansPrimary Care PhysiciansPulmonologistsNurse PractitionersFellowsRadiation OncologistsMedical OncologistsPrimary Care Providers